Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week double-blind treatment period assessing the efficacy and safety of lixisenatide in patients with Type 2 diabetes insufficiently controlled with insulin glargine and metformin. - GET GOAL DUO 1

Next Previous
Trial Profile

A randomized, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week double-blind treatment period assessing the efficacy and safety of lixisenatide in patients with Type 2 diabetes insufficiently controlled with insulin glargine and metformin. - GET GOAL DUO 1

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lixisenatide (Primary) ; Insulin glargine; Metformin; Pioglitazone; Rosiglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms GETGOAL-DUO-1
  • Sponsors Sanofi

    • Most Recent Events

    • 12 Feb 2023 Results from a pooled analysis of GetGoal-Duo 1, GetGoal-L, and GetGoal-L-C studies for Asian patients with type 2 diabetes were published in the Diabetes Therapy
    • 15 Sep 2017 Results of an exploratory analysis comparing efficacy of simultaneous administration of iGlarLixi in LixiLan-O ( N =469) trial versus sequential administration of insulin glargine followed by addition of lixisenatide in GetGoal Duo-1 ( N =223) trial, presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
    • 13 Jun 2017 Results of propensity score-matched analysis to compare this study and Lixi- Lan-O Trial presented at the 77th Annual Scientific Sessions of the American Diabetes Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top